Summary
Hanne Cloetta Lang has extensive leadership experience in R&D Quality and Clinical Operations within the pharmaceutical industry, primarily at Novo Nordisk. She has held multiple Vice President and CVP roles, demonstrating a progression through various critical functions in drug development. theorg
She is a proponent and leader in the implementation of Risk-Based Monitoring (RBM) in clinical trials, advocating for its role in ensuring drug safety, improving data quality, and optimizing resource allocation. Her work in this area aligns with regulatory updates and industry best practices. worldpharmaceuticals
Hanne Cloetta Lang has been involved in cross-industry initiatives to standardize clinical trial practices, notably serving as Novo Nordisk's oversight committee member for TransCelerate Biopharma Inc. This involvement underscores her commitment to advancing pharmaceutical R&D through collaboration and innovation. theorg+1
Her current role as CVP R&D Quality at Novo Nordisk involves leading quality assurance for Device & Delivery Solutions (DDS) and Cell Therapy areas, indicating expertise in cutting-edge pharmaceutical technologies and quality management in complex product development. theorg+1